Cigna's Evernorth announced a $100 million investment to support a new artificial intelligence-powered pharmacy program on Wednesday. This initiative aims to enhance patient care and streamline prescription processing, reflecting the growing trend in specialty pharmacy, which has attracted significant investments from health insurers and private equity firms.
Key Details
The investment is part of Cigna's broader strategy to improve clinical care and patient outcomes while addressing the rising costs associated with specialty drugs. Specialty medications, including biologics and anti-obesity treatments, now account for over half of total prescription spending for many health plans, according to the company. Matt Perlberg, president of Evernorth, stated,
Patients navigating complex health conditions need comprehensive, expert support… This investment enables care teams to focus more on clinical care.
This move follows a surge of investment in the specialty pharmacy sector, with major players like CVS Health, Humana, and UnitedHealth Group also expanding their offerings. The increasing demand for specialty drugs, particularly anti-obesity medications, has prompted employers to report that these costs can represent 60% or more of their total drug spending.
Background
Cigna's investment comes amid a broader economic context where artificial intelligence is reshaping various industries. The U.S. economy grew at a 2.1% annualized rate in the first quarter of the year, largely fueled by AI-related investments, according to Commerce Department data. However, this growth has highlighted disparities, as lower-income Americans continue to experience stagnant wage growth and rising living costs.
Related coverage: Kraken Sues Auditor Mazars for $22 Million After Exit.
Cigna's investment is likely to influence the healthcare sector, particularly affecting shares of companies involved in specialty pharmacy and AI technologies. Investors may respond to the potential for increased efficiency and reduced costs in prescription management. Watch for further developments in specialty pharmacy strategies and how they impact overall healthcare spending in the coming months.